卡培他滨治疗对氟尿嘧啶耐药的晚期转移性结直肠癌的效果观察

Efficacy of capecitabine in patients with 5-FU-resistant metastatic colorectal cancer

47例对5- 氟尿嘧啶(5- FU)耐药的晚期转移性结直肠癌患者接受卡培他滨(希罗达)治疗,根据WHO标准评价疗效及毒性反应,总有效率为17. 0%,平均反应持续时间为8 5个月, 原病情进展的患者有44. 7%经治疗后病情稳定, 病情稳定的平均时间4 8个月。有50%的病例在5个月内存在病情不再进展的可能性,自应用希罗达后的平均生存期为10 4个月,治疗前体质量持续下降的患者经3 个周期治疗有83. 0%(39/47)体质量稳定或增加。毒性反应中以恶心、腹泻、食欲减退、疲劳、手足综合征最为常见。初步研究结果提示,已经对5 -FU产生耐药性的晚期结直肠癌患者,经希罗达治疗,仍然有较高的有效率,而且毒性反应可以耐受,不影响继续治疗。

Forty-seven patients with documented progression of metastatic colorectal cancer were treated with capecitabine [2 510 mg/(m2·d),twice a day, 14 day continuously,one cycle every 3 weeks].Tumor response and toxicity were assessed by using WHO criteria. The overall response rate was 8/47(17.0%),median duration response was 8.5 months.There was a high rate of disease stabilization (44.7%) with a median duration of 4.8 months. The probability of being free from progression at 5 months was 50%. Median survival time from first administration of capecitabine was 10.4 months. There was weight stabilization or gain in 83.0%(39/47). In conclusion, the efficacy of capecitabine in patients with 5-FU-resistant metastatic colorectal cancer is encouraging. The toxicity of capecitabine is tolerable, and do not disturb continous chemotherapy.